Direct site-specific labeling of the cys-tag moiety in scVEGF with technetium 99m

Bioconjugate Chemistry

Volumn 19, Issue 5, 2008, Pages 1049-1054

  Levashova, Zoia ^a   Backer, Marina ^b   Backer, Joseph M ^b   Blankenberg, Francis G ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SIBTECH INC   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; MOLECULAR IMAGING; PATIENT MONITORING; TUMORS;

AGENT BASED; ANGIOGENESIS; DRUG DEVELOPMENT; FUNDAMENTAL FEATURES; IMAGING AGENT; LABELINGS; SITE-SPECIFIC; TECHNETIUM-99M; TUMOR DEVELOPMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR;

CHELATION;

CHELATE; TECHNETIUM 99M; TIN; TRACER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER MODEL; CHELATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; RECEPTOR BINDING; SCATCHARD PLOT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 44349154751     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc7004818     Document Type: Article

References (38)

1. Kerbel, R., and Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-39.
2. Gille, J. (2006) Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp. Dermatol. 15, 175-186.
3. Gwyther, S. J., and Schwartz, L. H. (2007) How to assess anti-tumour efficacy by imaging techniques. Eur. J. Cancer. [Online early access]. Published online Nov 38, 2007.
4. Izzedine, H., Rixe, O., Billemont, B., Baumelou, A., and Deray, G. (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am. J. Kidney Dis. 50, 203-218.
5. Cabebe, E., and Wakelee, H. (2007) Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr. Treat. Options Oncol. 8, 15-27.
6. Haubner, R., and Wester, H. J. (2004) Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Design 10, 1439-1455.
7. Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., and Thrall, J. H. (2005) Imaging angiogenesis: applications and potential for drug development. J. Natl.Cancer Inst. 97, 172-87.
8. Cai, W., Rao, J., Gambhir, S. S., and Chen, X. (2006) How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 5, 2624-33.
9. Shibuya, M. (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9, 225-230.
10. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936.
11. Rahimi, N. (2006) VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front. Biosci. 11, 818-829.
12. Ribatti, D., Nico, B., Crivellato, E., Roccaro, A. M., and Vacca, A. (2007) The history of the angiogenic switch concept. Leukemia 21, 44-52.
13. Walsh, D. A. (2007) Pathophysiologic mechanisms of angiogenesis. Adv. Clin. Chem. 44, 187-221.
14. Blankenberg, F. G., Mandl, S., Cao, Y. A., O'Connell-Rodwell, C., Contag, C., Mari, C., Gaynutdinov, T. I., Vanderheyden, J. L., Backer, M. V., and Backer, J. M. (2004) Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J. Nucl. Med. 45, 1373-1380.
15. Backer, M. V., Gaynutdinov, T. I., Patel, V., Bandyopadhyaya, A. K., Thirumamagal, B. T., Tjarks, W., Barth, R. F., Claffey, K., and Backer, J. M. (2005) Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther. 4, 1423-1429.
16. Blankenberg, F. G., Backer, M. V., Levashova, Z., Patel, V., and Backer, J. M. (2006) In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF. Eur. J. Nuclear Med. Mol. Imag. 33, 841-848.
17. Backer, M. V., Levashova, Z., Patel, V., Jehning, B. T., Claffey, K., Blankenberg, F. G., and Backer, J. M. (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF driven probes. Nat. Med. 13, 504-509.
18. Thirumamagal, B. T. S., Zhao, X. B., Bandyopadhyaya, A. K., Narayanasamy, S., Johnsamuel, J., Tiwari, R., Golightly, D. W., Patel, V., Jehning, B. T., Backer, M. V., Barth, R. F., Lee, R. J., Backer, J. M., and Tjarks, W. (2006) Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjugate Chem. 17, 1141-1150.
19. Backer, M. V., Patel, V., Jehning, B. T., Claffey, K., and Backer, J. M. (2006) Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials 27, 5452-5458.
20. Backer, M., Patel, V., Jehning, B., and Backer, J. M. (2006) Self-assembled "dock and lock" system for linking payloads to targeting proteins. Bioconjugate Chem. 17, 912-919.
21. Backer, M. V., Patel, V., Jehning, B. T., Claffey, K., Karginov, V. A., and Backer, J. M. (2007) Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob. Agents Chemother. 51, 245-251.
22. Backer, M. V., Levashova, Z., Levenson, R., Blankenberg, F. G., and Backer, J. M. (2008) Cysteine-Containing Fusion Tag for Site-Specific Conjugation of Therapeutic and Imaging Agents to Targeting Proteins. In Methods in Molecular Medicine, Peptide-Based Drug Design (Otros, L., Ed.) The Humana Press Inc., Totowa, NJ (In press).
23. George, A. J., Jamar, F., Tai, M. S., Heelan, B. T., Adams, G. P., McCartney, J. E., Houston, L. L., Weiner, L. M., Oppermann, H., and Peters, A. M. (1995) Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl. Proc. Natl. Acad. Sci. U.S.A. 92, 8358-8362.
24. Bogdanov, A., Jr., Simonova, M., and Weissleder, R. (1998) Design of metal-binding green fluorescent protein variants. Biochim. Biophys. Acta 1397, 56-64.
25. 99mTc. Bioconjugate Chem. 11, 918-925.
26. Backer, M. V., Gaynutdinov, T. I., Gorshkova, I. I., Crouch, R. J., Hu, T., Aloise, R., Arab, M., Przekop, K., and Backer, J. M. (2003) Humanized docking system for assembly of targeting drug delivery complexes. J. Controlled Release 89, 499-511.
27. Larsen, S. K., Solomon, H. F., Caldwell, G., and Abrams, M. J. (1995) [99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjugate Chem. 6, 635-638.
28. Tang, X. N., Wang, Q., Koike, M. A., Cheng, D., Goris, M. L., Blankenberg, F. G., and Yenari, M. A. (2007) Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J. Nucl. Med. 48, 1822-1828.
29. Backer, M. V., and Backer, J. M. (2001) Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjugate Chem. 12, 1066-73.
30. Backer, M. V., and Backer, J. M. (2001) Functionally active VEGF fusion proteins. Protein Expr. Purif. 23, 1-7.
31. Li, S., Peck-Radosavljevic, M., Koller, E., Koller, F., Kaserer, K., Kreil, A., Kapiotis, S., Hamwi, A., Weich, H. A., Valent, P., Angelberger, P., Dudczak, R., and Virgolini, I. (2001) Characterization of (123) I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int. J. Cancer. 91, 789-796.
32. Li, S., Peck-Radosavljevic, M., Kienast, O., Preitfellner, J., Hamilton, G., Kurtaran, A., Pirich, C., Angelberger, P., and Dudczak, R. (2003) Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann. Oncol. 14, 1274-1277.
33. Li, S., Peck-Radosavljevic, M., Kienast, O., Preitfellner, J., Havlik, E., Schima, W., Traub-Weidinger, T., Graf, S., Beheshti, M., Schmid, M., Angelberger, P., and Dudczak, R. (2004) Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q. J. Nucl. Med. Mol. Imaging 48, 198-206.
34. 165 as a potential tumor marker. Nucl. Med. Biol. 32, 431-436.
35. Cai, W., Chen, K., Mohamedali, K. A., Cao, Q., Gambhir, S. S., Rosenblum, M. G., and Chen, X. (2006) PET of vascular endothelial growth factor receptor expression. J. Nucl. Med. 47, 2048-2056.
36. Wang, H., Cai, W., Chen, K., Li, Z. B., Kashefi, A., He, L., and Chen, X. (2007) A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur. J. Nucl. Med. Mol. Imaging 34, 2001-10.
37. Lu, E., Wagner, W. R., Schellenberger, U., Abraham, J. A., Klibanov, A. L., Woulfe, S. R., Csikari, M. M., Fischer, D., Schreiner, G. F., Brandenburger, G. H., and Villanueva, F. S. (2003) Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 108, 97-103.
38. Chan, C., Sandhu, J., Guha, A., Scollard, D. A., Wang, J., Chen, P., Bai, K., Lee, L., and Reilly, R. M. (2005) A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111) ln for imaging tumor angiogenesis. J. Nucl. Med. 46, 1745-1752.